Study identifies PPP2R5C blood marker that may detect Alzheimer’s disease earlier

Researchers have identified a potential new biomarker in blood that could signal the early stages of Alzheimer’s disease (AD). The study, published in Cell Reports Medicine, focuses on levels of a protein called protein phosphatase 2 regulatory subunit B’β (PPP2R5C) and its connection to the development of AD pathology.

Understanding Alzheimer’s and the Search for Early Detection

The Challenge of Early Diagnosis

Alzheimer’s disease, the most common form of dementia, is characterized by changes in the brain that begin years, even decades, before symptoms appear. Identifying reliable biomarkers – measurable indicators of a disease process – is crucial for intervening early, potentially before irreversible damage occurs. Current diagnostic methods, such as positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) analysis, can be expensive and invasive, limiting their widespread use.

The Role of Tau and PP2A

A key feature of AD is the abnormal phosphorylation of tau protein, leading to the formation of neurofibrillary tangles (NFTs) and neuronal dysfunction. Protein phosphatase 2A (PP2A) plays a significant role in regulating tau phosphorylation, accounting for approximately 70% of total tau phosphatase activity in the human brain. PPP2R5C is a component of PP2A and is highly expressed in the brain; prior research had linked a genetic variation in the PPP2R5C gene to AD risk.

Did You Know? Researchers found that PPP2R5C levels decreased as early as Braak stage II, a phase of AD pathology where neurofibrillary tangles are still relatively limited.

The Research Findings: From Exosomes to Plasma

Identifying PPP2R5C in Neuron-Derived Exosomes

The study began by examining PPP2R5C levels in neuron-derived exosomes (NDEs) isolated from plasma samples. Initial analysis compared four cognitively normal individuals, four with presymptomatic familial AD, and five with familial AD. Researchers observed a progressive decrease in PPP2R5C levels from the presymptomatic group to those with established AD, compared to the cognitively normal controls.

Validating the Findings in Larger Cohorts

These initial findings were then validated in a larger group consisting of 32 cognitively normal controls, 20 with sporadic AD, and 12 with amnestic mild cognitive impairment (aMCI). This analysis further supported the association between reduced PPP2R5C expression and early AD processes. To make testing more practical, researchers also examined total PPP2R5C levels in plasma itself.

Plasma PPP2R5C as a Potential Biomarker

Analysis of a third cohort, including 15 familial AD patients and 15 cognitively normal controls, showed significantly lower plasma PPP2R5C levels in those with AD. Specifically, aMCI patients had approximately 61.3% lower levels, and AD patients had 31.6% lower levels, compared to controls. Plasma PPP2R5C distinguished AD from controls with an area under the receiver operating characteristic curve (AUROC) of 0.8494 and aMCI from controls with an AUROC of 0.7360.

Expert Insight: The identification of a potential blood-based biomarker like PPP2R5C is a significant step forward. Current diagnostic tools are often invasive or expensive, limiting their use in widespread screening. A readily accessible biomarker could allow for earlier detection and potentially, more effective interventions.

How PPP2R5C Might Influence Alzheimer’s Development

The Connection to Tau Regulation

Researchers found that PPP2R5C interacts with tau protein. Increasing PPP2R5C expression reduced phosphorylated tau levels and enhanced PP2A enzymatic activity. Conversely, reducing PPP2R5C expression decreased PP2A activity, suggesting a direct regulatory role. Experiments also showed that PPP2R5C promotes tau degradation through a process involving the autophagolysosomal pathway.

The Role of ULK1

The study also investigated the involvement of unc-51-like kinase 1 (ULK1), a regulator of autophagy. Researchers observed a negative correlation between PPP2R5C expression and phosphorylated ULK1, and evidence suggesting that PPP2R5C binds to ULK1. This suggests a potential mechanism by which PPP2R5C influences tau clearance.

What’s Next?

While these findings are promising, the researchers emphasize that further validation is needed. Larger, more diverse studies are necessary to confirm these results and assess the reliability of PPP2R5C as a diagnostic marker. Standardization of the assay and further research into its reproducibility will be essential before it can be used in clinical settings. Future research could focus on developing therapies to increase PPP2R5C levels, potentially slowing or preventing the progression of Alzheimer’s disease. It is also likely that researchers will investigate whether PPP2R5C levels can be used to monitor the effectiveness of new AD treatments.

Frequently Asked Questions

What is a biomarker?

According to the study, a biomarker is a measurable indicator of a disease process.

What is the significance of the AUROC values mentioned in the study?

The area under the receiver operating characteristic curve (AUROC) is a measure of how well a biomarker can distinguish between different groups. An AUROC of 1.0 represents perfect discrimination, while an AUROC of 0.5 indicates no discriminatory power.

What is the autophagolysosomal pathway?

The study indicates that the autophagolysosomal pathway is involved in PPP2R5C-mediated tau clearance, and is a cellular process responsible for degrading and removing damaged or unnecessary cellular components.

Given these early findings, how might the development of accessible biomarkers like PPP2R5C change the landscape of Alzheimer’s disease management in the years to come?